Bibliographies thématiques / Benralizumab

Sommaire

Articles de revues
Thèses
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « Benralizumab »

Auteur : Grafiati

Publié le 14 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Benralizumab ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Benralizumab"

Antoniu, S. A. « Benralizumab ». Drugs of the Future 39, n^o 7 (2014) : 463. http://dx.doi.org/10.1358/dof.2014.039.07.2156125.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Zhuravleva, M. V., S. N. Avdeev, Yu V. Gagarina et T. V. Marin. « Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings ». FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, n^o 2 (27 juillet 2022) : 175–86. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.143.

Texte intégral

Résumé :

Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe asthma (SA).Material and methods. The cost minimization and budget impact analysis methods were used. The current practice of treating patients with SA with benralizumab in hospital settings at the expense of compulsory medical insurance funds was compared with the simulated practice. The simulated price was calculated as half patients receiving benralizumab in the hospital transferred to outpatient facilities at the expense of regional funds for 3 years. Direct medical costs included drug cost and outpatient patient monitoring services cost.Results. The direct medical costs associated with benralizumab therapy in outpatient facilities were lower than the costs required for benralizumab therapy in the hospital settings and amounted to 0.99 million rubles versus 1.17 million rubles per one patient per year, respectively. Thus, the use of benralizumab in outpatient facilities leads to savings of 185 thousand rubles (16%). In 2021, 93 patients were prescribed benralizumab in hospital settings. The expansion of the application of benralizumab use in outpatient facilities will lead to a reduction in medical costs in the first year of therapy (when switching 16.7% of patients) by 5.9 million rubles (4,9%). The consistent expansion of the practice of benralizumab use in outpatient facilities over a 3-year horizon (when switching 50% of patients) will lead to a reduction in medical costs by 46.6 million rubles (12.1%).Conclusion. Expansion of benralizumab use in outpatient facilities with a new form of autoinjector (pen-injector device) will lead to savings in medical costs and reduce the burden on the health care system, thus it is economically feasible.

Styles APA, Harvard, Vancouver, ISO, etc.

Bourdin, Arnaud, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner et Xiao Xu. « Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma : a systematic review ». European Respiratory Journal 52, n^o 5 (11 octobre 2018) : 1801393. http://dx.doi.org/10.1183/13993003.01393-2018.

Texte intégral

Résumé :

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy comparisons.After matching adjustment, benralizumab and mepolizumab reduced exacerbations versus placebo by 52% and 49%, respectively (rate ratio [RR] 0.94, 95% CI 0.78–1.13; n=1524) and reduced the rate of exacerbations requiring hospitalisation/emergency department visit by 52% and 52%, respectively (RR 1.00, 95% CI 0.57–1.75; n=1524). Benralizumab and mepolizumab similarly improved pre-bronchodilator forced expiratory volume in 1 s at 32 weeks (difference 0.03 L, 95% CI −0.06–0.12; n=1443). Benralizumab and reslizumab patient populations were too dissimilar to generate a sufficient effective sample size to produce a reliable estimate for MAIC.MAIC is a robust way to indirectly compare treatment efficacies from trials with heterogeneous patient populations. When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.

Styles APA, Harvard, Vancouver, ISO, etc.

Ando, Koichi, Akihiko Tanaka et Hironori Sagara. « Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma : A Systematic Review ». International Journal of Molecular Sciences 21, n^o 3 (30 janvier 2020) : 889. http://dx.doi.org/10.3390/ijms21030889.

Texte intégral

Résumé :

No head-to-head trials have compared the efficacy and safety between the licensed dosage and administration dosage of dupilumab and benralizumab for inadequately controlled asthma. We conducted an indirect treatment comparison to estimate differences in the efficacy and safety between dupilumab and benralizumab for inadequately controlled asthma using the Bayesian approach. The primary efficacy endpoint was annual exacerbation rate (AER). A subgroup analysis by blood eosinophil count was also performed. The primary safety endpoint was the incidence of any adverse events (AAEs). The results demonstrate that there was no significant difference in the AER between dupilumab and benralizumab in overall patients and the subgroup with the blood eosinophil count of <150. However, the AER was significantly lower in the dupilumab group than in the benralizumab group in the subgroup with a blood eosinophil count of ≥150 but <300, and ≥300 with the rate ratio and 95% credible interval of 0.51 (0.29–0.92) and 0.58 (0.39–0.84), respectively. There was no significant difference in the AAEs between the dupilumab and benralizumab groups. This indirect treatment comparison indicates that dupilumab is superior to benralizumab in patients with inadequately controlled asthma having higher blood eosinophil counts. A direct comparison is required to provide definitive evidence. Systematic Review Registration: UMIN-CTR no. UMIN000036256.

Styles APA, Harvard, Vancouver, ISO, etc.

Bleecker, Eugene R., Michael E. Wechsler, J. Mark FitzGerald, Andrew Menzies-Gow, Yanping Wu, Ian Hirsch, Mitchell Goldman, Paul Newbold et James G. Zangrilli. « Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma ». European Respiratory Journal 52, n^o 4 (23 août 2018) : 1800936. http://dx.doi.org/10.1183/13993003.00936-2018.

Texte intégral

Résumé :

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analysis used pooled data from the SIROCCO (ClinicalTrials.gov identifier NCT01928771) and CALIMA (ClinicalTrials.gov identifier NCT01914757) Phase III studies. Patients aged 12–75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β2-agonists received benralizumab 30 mg subcutaneously every 8 weeks (Q8W, first three doses every 4 weeks (Q4W)), Q4W or placebo. Baseline factors that influenced benralizumab efficacy were evaluated, including oral corticosteroid (OCS) use, nasal polyposis, pre-bronchodilator forced vital capacity (FVC), prior year exacerbations and age at diagnosis. Efficacy outcomes included annual exacerbation rate and change in pre-bronchodilator forced expiratory volume in 1 s at treatment end relative to placebo.Benralizumab Q8W treatment effect was enhanced with each baseline factor for all patients and those with ≥300 eosinophils·μL−1 relative to the overall population. OCS use, nasal polyposis and FVC <65% of predicted were associated with greater benralizumab Q8W responsiveness for reduced exacerbation rate for patients with <300 eosinophils·μL−1.Baseline clinical factors and blood eosinophil counts can help identify patients potentially responsive to benralizumab.

Styles APA, Harvard, Vancouver, ISO, etc.

Yamada, Hideyasu, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi et al. « Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma ». PLOS ONE 16, n^o 3 (11 mars 2021) : e0248305. http://dx.doi.org/10.1371/journal.pone.0248305.

Texte intégral

Résumé :

Purpose To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement. Patients and methods Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab treatment were included in this analysis. Pre-treatment clinical factors were compared between responders and non-responders according to improvements in ACT or FEV1. Correlations between the sums of increased Type 2-related inflammatory parameters and changes of ACT or FEV1 were also evaluated before and after the 4-month treatment. A two-step cluster analysis was performed to identify distinct phenotypes related to benralizumab responsiveness in terms of FEV1. Results At the 4-month timepoint, all parameters, except for FeNO, were significantly improved after benralizumab treatment. FEV1 responders were associated with higher levels of Type 2-related inflammatory parameters. An improvement in FEV1 but not in ACT was clearly associated with increases in the sums of increased type 2-related inflammation parameters (p = 0.0001). The cluster analysis identified 5 distinct phenotypes of severe eosinophilic asthma according to the variable FEV1 responsiveness to benralizumab. The greatest response was found in the distinct phenotype of severe eosinophilic asthma, which was characterized by modest increase in total IgE and FeNO relative to blood eosinophils with least exposure to smoking. Conclusion This study, to the best of our knowledge, is the first cluster analysis to report distinct phenotypes related to clinical benralizumab response in a real-world population with severe eosinophilic asthma. These results may help to predict responsiveness to benralizumab in patients with severe eosinophilic asthma.

Styles APA, Harvard, Vancouver, ISO, etc.

Titova, Olga N., Natalia A. Kuzubova, Daria B. Sklyarova et Maria A. Petrova. « The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice ». PULMONOLOGIYA 31, n^o 5 (20 octobre 2021) : 628–34. http://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634.

Texte intégral

Résumé :

To evaluate the effectiveness of benralizumab in patients with the eosinophilic phenotype of severe asthma in real clinical practice after a year of therapy.Methods. During Benralizumab therapy, 13 patients with severe eosinophilic asthma (average age – 55.44 ± 7.18 years old) were examined twice: before the treatment and after 1 year of benralizumab therapy. The assessment included collection of complaints, medical history, current therapy, Asthma Control Questionnaire (ACQ-5) test, absolute blood count of eosinophils, spirometry.Results. All patients initially had pronounced eosinophilia of 577.5 ± 356.4 cells/μl. After 1 year of using benralizumab, the eosinophil count decreased by 96.15%. During therapy, the ACQ-5 index decreased from 1.63 ± 0.62 to 0.73 ± 0.41 in the study patients, which corresponded to the achievement of asthma control. The forced expiratory volume in 1 second (FEV1) increased by 23 %. The number of exacerbations decreased by 58.09%. 12 (92.31%) patients were on oral corticosteroids (OCS) (10 ± 2.17 mg of prednisolone daily) before benralizumab therapy. All subjects noted a decrease in night and day symptoms over time and were able to reduce the use of OCS. 5 (38.46%) patients achieved complete elimination of daily OCS use, 7 (53.84%) patients were able to reduce their daily OCS dose.Conclusion. Benralizumab therapy as an add-on maintenance treatment in patients with eosinophilic phenotype of severe asthma contributes to a significant decrease in peripheral blood eosinophils, which mediates an improvement in asthma control, an increase in FEV1, a reduction in the number of exacerbations, and a decrease in the need for the OCS usage. Careful monitoring of long-term adverse events is necessary during treatment with benralizumab.

Styles APA, Harvard, Vancouver, ISO, etc.

Tsurumaki, Matsuyama, Ezawa, Koga, Yatomi, Aoki-Saito, Chikamatsu et Hisada. « Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis ». Medicina 55, n^o 7 (3 juillet 2019) : 336. http://dx.doi.org/10.3390/medicina55070336.

Texte intégral

Résumé :

A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy. Six months after BT, a diagnosis of severe asthma with eosinophilic chronic rhinosinusitis (ECRS) was made and benralizumab treatment was initiated; the blood eosinophil count subsequently decreased and lung function improved, thereby permitting OCS dose tapering. Surprisingly, benralizumab both reduced nasal polyps and ameliorated ECRS. Thus, benralizumab may be a useful drug for the rapid treatment of severe asthma with ECRS, especially in patients with hypereosinophilia.

Styles APA, Harvard, Vancouver, ISO, etc.

Nedogoda, Sergey Vladimirovich, Alla Sergeevna Salasyuk, Irina Nikolaevna Barykina, Victoria Olegovna Smirnova et Maksim Yurevich Frolov. « Сost of the Biologacal Therapy for Severe Brochcial Asthma Treatment at Inpatient and Day Care Setting ». Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), n^o 1 (39) (1 mai 2020) : 61–69. http://dx.doi.org/10.31556/2219-0678.2020.39.1.061-069.

Texte intégral

Résumé :

Objective: to assess the cost of the severe bronchial asthma (BA) treatment with various biological agents at inpatient and day care setting from the compulsory medical insurance (CMI) system perspective. Methods. The authors constructed the MS Excel® analytical decision-making model and calculated the CMI system’s costs of severe BA treatment with various biological drugs at inpatient and day care setting. The costs of treatment with benralizumab, dupilumab, omalizumab, reslizumab and mepolizumab were compared. The cost difference between benralizumab and other drugs was identified taking into account the frequency of the drugs’ administration. The first administration was assumed to be inpatient, followed by the administrations in day care ward. Results. The use of benralizumab reduces the expenses of the CMI system by 0.8 million rubles per patient (–39%) compared with omalizumab, mepolizumab, resizumab and by 2.9 million rubles per patient (–69%) versus dupilumab due to the lowest frequency of administration, therefore less hospitalizations for therapy. With a 5-year modeling horizon, benralizumab therapy allows to reduce the CMI system expenses by 4.5 million rubles (–48%) compared with omalizumab, mepolizumab, reslizumab and by 13.9 million rubles (–74%) compared with dupilumab. The use of benralizumab will release 5–7 cases per patient per year compared to omalizumab, resizumab and mepolizumab and 18–20 cases per patient per year compared to dupilumab. Conclusion. Benralizumab therapy in patients with severe BA in inpatient and day care settings will lead to the optimization of CMI expenditures and more rational use of budgets allocated to hospitals.

Styles APA, Harvard, Vancouver, ISO, etc.

Markham, A. « Benralizumab : First Global Approval ». Drugs 78, n^o 4 (20 février 2018) : 505–11. http://dx.doi.org/10.1007/s40265-018-0876-8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Benralizumab"

Laura, Bergantini. « Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients ». Doctoral thesis, Università di Siena, 2020. http://hdl.handle.net/11365/1120137.

Texte intégral

Résumé :

New anti IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, KL-6 and lymphocyte subsets as bioindicators of airways hyper-responsiveness and remodelling and to phenotype patients according to their answer to the treatment. L‐selectin mediates leukocyte rolling of lung endothelium and its expression on T cells is increased in asthma patients. Regulatory T cells (Tregs) suppress inflammation by secreting a wide variety of cytokines that inhibit T cell proliferation. A cohort of 28 patients affected by severe eosinophilic asthma were treated with anti IL-5 drugs: 20 with Mepolizumab and 8 with Benralizumab. Lymphocytes subsets, Regulatory T cells and CD4+CD62L+ cells were analyzed through flow cytometry, Serum L-selectin quantification was performed by bead-based multiplex analysis, while KL-6 was analyzed through CLEIA. Clinical, functional and immunological data at baseline (T0), after one month (T1) and 6 months of therapy were collected in a database. All treated patients showed variations in FEV1, FEV1/FVC ratio and peripheral eosinophils for both drugs. Mepolizumab treated patients also showed significant differences between T0 and T1 in CD8+ and NK-T like cells percentages and a significant increase in L-selectin concentrations. Stratifying the cohort of our patients in “early responders and partial responders at T0 they showed significant differences in peripheral eosinophils, sL-selectin, and KL-6, while no differences were found at T0 between “early responders” and “partial responders” patients treated with Benralizumab. In a subgroup of 14 mepolizumab treated patients, immunological data showed an increase in Tregs and CD4+CD62L+ at T1. Soluble L-selectin concentrations were lower at T1. CD45+ and CD62L+ cell features differed significantly in early and partial responders before and after therapy. The FEV1/FVC ratio showed an indirect correlation with L-selectin levels (r=-0.6, p=0.03), peripheral eosinophilia (r=-0.7, p=0.01). This real-life study provides new insights for the personalized approach to severe asthma therapy. Although preliminary, the results indicate that besides to peripheral eosinophils, other molecules are useful as biomarkers of early response that can also involving in the pathogenesis of severe asthma. Mepolizumab therapy was found to modulate immune response, restoring immune balance in patients with SEA. L-selectin and Tregs were also proposed as biomarkers of response to mepolizumab treatment.

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Benralizumab"

« Benralizumab ». Dans Encyclopedia of Molecular Pharmacology, 312. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-57401-7_300078.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Benralizumab"

Harrison, T., A. L. Fuhlbrigge, M. Fagerås, A. Jauhiainen, L. E. J. M. Scheepers, J. Zangrilli et C. A. Da Silva. « Benralizumab Reduces Asthma Worsening Episodes ». Dans American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7087.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Bleecker, Eugene R., Xingnan Li, Paul Newbold, Ian Hirsch, Huashi Li, James Zangrilli, Mitchell Goldman et Deborah A. Meyers. « Benralizumab treatment and SARP cluster analysis ». Dans ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa1659.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Singh, D., G. J. Criner, A. Agusti, M. Bafadhel, J. Söderström, G. Luporini Saraiva, Y. Song et al. « Effect of benralizumab on recurrent COPD exacerbations ». Dans ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.3906.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Samant, M., P. Lyons et M. Castro. « Benralizumab : Not Just for Your Poorly Controlled Asthmatic ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1355.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Jackson, David J., Tim Harrison, Francesco Menzella, Vivian H. Shih, Annie Burden et Esther Garcia Gil. « Identifying super-responders to benralizumab in severe asthma ». Dans ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3734.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Marchewski, H., G. Schwefel, K. Bratke, JC Virchow et M. Lommatzsch. « Benralizumab reduziert Blut-Basophile bei Patienten mit schwerem Asthma ». Dans 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3403072.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Newbold, Paul, Hao Liu, Tuyet-Hang Pham, Gautam Damera et Sriram Sridhar. « Modulation of inflammation by benralizumab in eosinophilic airway disease ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4902.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nair, Parameswaran, Manali Mukherjee, Hui Fang Lim, Chynna Huang, Katherine Radford, Louis-Philippe Boulet, Delbert Dorscheid, James G. Martin et Roma Sehmi. « Benralizumab attenuates airway eosinophilopoietic processes in prednisone-dependent asthma ». Dans ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa3217.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Kooner, H. K., M. J. Mcintosh, R. L. Eddy, A. Gendron, C. Licskai, C. Yamashita et G. Parraga. « CT Mucus Score Predicts Benralizumab Response in Severe Asthma ». Dans American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4531.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Gutiérrez Lorenzo, M., L. Rodríguez De Francisco, J. Romero Puerto, P. Ciudad Gutiérrez et P. del Valle Moreno. « 4CPS-191 Switch to benralizumab for severe eosinophilic asthma ». Dans 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.403.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Benralizumab"

Zhou, Wen. Does benralizumab effectively treat chronic obstructive pulmonary disease ? a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, avril 2020. http://dx.doi.org/10.37766/inplasy2020.4.0039.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!